Src is a target molecule of mannose against pancreatic cancer cells growth in vitro & amp; in vivo
文献类型：期刊论文
| 作者 | Xie, Jianhao2,3; Wu, Shengjie2,3; Liao, Wenfeng2; Ning, Jingru2,4; Ding, Kan1,2,3,5
|
| 刊名 | GLYCOBIOLOGY
 |
| 出版日期 | 2023-09-02 |
| 页码 | 18 |
| ISSN号 | 0959-6658 |
| 关键词 | computational biology mannose network pharmacologypancreatic cancer Src |
| DOI | 10.1093/glycob/cwad070 |
| 通讯作者 | Ding, Kan(dingkan@simm.ac.cn) |
| 英文摘要 | Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer with limited treatment options. Mannose, a common monosaccharide taken up by cells through the same transporters as glucose, has been shown to induce growth retardation and enhance cell death in response to chemotherapy in several cancers, including PDAC. However, the molecular targets and mechanisms underlying mannose's action against PDAC are not well understood. In this study, we used an integrative approach of network pharmacology, bioinformatics analysis, and experimental verification to investigate the pharmacological targets and mechanisms of mannose against PDAC. Our results showed that the protein Src is a key target of mannose in PDAC. Additionally, computational analysis revealed that mannose is a highly soluble compound that meets Lipinski's rule of five and that the expression of its target molecules is correlated with survival rates and prognosis in PDAC patients. Finally, we validated our findings through in vitro and in vivo experiments. In conclusion, our study provides evidence that mannose plays a critical role in inhibiting PDAC growth by targeting Src, suggesting that it may be a promising therapeutic candidate for PDAC. |
| WOS关键词 | NETWORK PHARMACOLOGY ; ORAL INGESTION ; LUNG-CANCER ; WEB SERVER ; POLYSACCHARIDES ; IDENTIFICATION ; SUPPRESSES ; ALTERS ; GENES |
| 资助项目 | We would like to thank Dr. Cheng-Hao Shao of Shanghai Changzheng Hospital for the clinical pancreatic cancer tissues. |
| WOS研究方向 | Biochemistry & Molecular Biology |
| 语种 | 英语 |
| 出版者 | OXFORD UNIV PRESS INC |
| WOS记录号 | WOS:001066109800001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/306146]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Ding, Kan |
| 作者单位 | 1.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Materia Med, SSIP Healthcare & Med Demonstrat Zone, Zhongshan 528400, Guangdong, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Materia Med, Carbohydrate Based Drug Res Ctr, CAS Key Lab Receptor Res,State Key Lab Drug Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China 3.Nanjing Univ Chinese Med, Sch Chinese Materia Med, 138 Xianlin Rd, Nanjing 210023, Peoples R China 4.Univ Chinese Acad Sci, 19 A Yuquan Rd, Beijing 100049, Peoples R China 5.Chinese Acad Sci, Shanghai Inst Materia Med, Carbohydrate Based Drug Res Ctr, CAS Key Lab Receptor Res,State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xie, Jianhao,Wu, Shengjie,Liao, Wenfeng,et al. Src is a target molecule of mannose against pancreatic cancer cells growth in vitro & amp; in vivo[J]. GLYCOBIOLOGY,2023:18. |
| APA | Xie, Jianhao,Wu, Shengjie,Liao, Wenfeng,Ning, Jingru,&Ding, Kan.(2023).Src is a target molecule of mannose against pancreatic cancer cells growth in vitro & amp; in vivo.GLYCOBIOLOGY,18. |
| MLA | Xie, Jianhao,et al."Src is a target molecule of mannose against pancreatic cancer cells growth in vitro & amp; in vivo".GLYCOBIOLOGY (2023):18. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。